{"id":"brinzolamide-1-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diplopia"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Eye pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting carbonic anhydrase, brinzolamide decreases the production of aqueous humor, thereby reducing intraocular pressure. This is particularly useful in the treatment of glaucoma and ocular hypertension.","oneSentence":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:36.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma"},{"name":"Secondary open-angle glaucoma"}]},"trialDetails":[{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT04944290","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2021-05-28","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":447},{"nctId":"NCT05022004","phase":"PHASE3","title":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2021-12-20","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":599},{"nctId":"NCT01722604","phase":"PHASE3","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-01","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":258},{"nctId":"NCT03896633","phase":"PHASE1, PHASE2","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2018-02-28","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":637},{"nctId":"NCT04024072","phase":"PHASE3","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2019-06-24","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":495},{"nctId":"NCT04523844","phase":"NA","title":"Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections","status":"COMPLETED","sponsor":"General Hospital of Athens Elpis","startDate":"2020-05-11","conditions":"Eye Diseases, Injection Complication, Intraocular Pressure","enrollment":47},{"nctId":"NCT02512042","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-04","conditions":"Glaucoma","enrollment":973},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT02339584","phase":"PHASE3","title":"Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-04-14","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":493},{"nctId":"NCT02770248","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With SIMBRINZA ®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-23","conditions":"Glaucoma","enrollment":162},{"nctId":"NCT03494257","phase":"NA","title":"Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2017-09-04","conditions":"Cataract, Intraocular Pressure","enrollment":62},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT00314171","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":437},{"nctId":"NCT00061516","phase":"PHASE3","title":"Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":78},{"nctId":"NCT00314158","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":523},{"nctId":"NCT02140060","phase":"PHASE2","title":"6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":327},{"nctId":"NCT01937312","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":282},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01978600","phase":"PHASE4","title":"Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":89},{"nctId":"NCT01312402","phase":"PHASE4","title":"Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome","status":"COMPLETED","sponsor":"Akron Children's Hospital","startDate":"2011-01","conditions":"Infantile Nystagmus Syndrome","enrollment":5},{"nctId":"NCT01357616","phase":"PHASE3","title":"Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":328},{"nctId":"NCT01309204","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1184},{"nctId":"NCT01310777","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":771},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT00759941","phase":"PHASE4","title":"A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Glaucoma","enrollment":86},{"nctId":"NCT01426867","phase":"PHASE2","title":"A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":103},{"nctId":"NCT01297920","phase":"PHASE3","title":"Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1062},{"nctId":"NCT00961649","phase":"PHASE2","title":"Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2009-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":195},{"nctId":"NCT01297517","phase":"PHASE3","title":"Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1001},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT00767494","phase":"PHASE3","title":"Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":17},{"nctId":"NCT00767481","phase":"PHASE3","title":"1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":6},{"nctId":"NCT00121147","phase":"NA","title":"Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2003-09","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZOPT®","AZOPT™","brinzolamide"],"phase":"phase_3","status":"active","brandName":"brinzolamide 1% ophthalmic suspension","genericName":"brinzolamide 1% ophthalmic suspension","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye. Used for Treatment of elevated intraocular pressure in patients with ocular hypertension or glaucoma, Secondary open-angle glaucoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}